Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis.

BACKGROUND AND OBJECTIVES The lymphotoxin beta (LTB) gene, localized to the major histocompatibility complex region on chromosome 6p21.3, has an important role in the formation of germinal center reactions and regulation of immune response and apoptosis. Our aim was to determine LTB gene expression in different hematologic neoplasias. DESIGN AND METHODS We determined the expression of LTB using quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) on a series of RNA samples from CD3(+) T cells and CD19(+) B cells isolated from peripheral blood (n=7); CD19(+) B cells isolated from lymph nodes (n=11) and from patients with acute lymphoblastic leukemia (ALL; n=16), acute myeloid leukemia (AML; n=43), chronic myeloid leukemia (CML; n=12), mantle cell lymphoma (MCL; n=19), chronic lymphocytic leukemia (CLL; n=32) and small lymphocytic lymphoma (SLL; n=22). RESULTS The expression level of LTB in CD3(+) T cells and CD19(+) B cells isolated from blood was ten to forty times lower than that in normal CD19(+) B cells isolated from lymph nodes. In malignant myeloid cells the expression levels were very low, whereas in malignant lymphoid cells the expression was higher than in myeloid cells, being highest in MCL and CLL (20.2+/-14.0 ng/microL and 81.0+/-116.3 ng/microL) and low in SLL (4.5+/-3.6 ng/microL; p=0.001). We did not find correlations between LTB expression and hematoclinical parameters (risk groups, immunophenotypes and overall survival). INTERPRETATION AND CONCLUSIONS A distinct difference in expression of LTB in CLL and SLL indicates that these morphologically similar B-cell malignancies are molecularly different. Further studies are needed to investigate the prognostic value of LTB and any role that LTB may have in determining whether the malignant B cells manifest a leukemia or lymphoma.

[1]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[2]  S. Bentley.  WHO Classification of Tumours: Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[3]  L. Fiette,et al.  IL-2-induced tumor necrosis factor (TNF)-β expression : further analysis in the IL-2 knockout model, and comparison with TNF-α, lymphotoxin-β, TNFR1 and TNFR2 modulation , 2001 .

[4]  G. Salles,et al.  Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas , 2000, Cancer Immunology, Immunotherapy.

[5]  J. Cullen,et al.  Woodchuck lymphotoxin-α, -β and tumor necrosis factor genes: structure, characterization and biological activity , 2000 .

[6]  A. Fusco,et al.  Sp1 and CTF/NF-1 transcription factors are involved in the basal expression of the Hmgi-c proximal promoter. , 1999, Biochemical and biophysical research communications.

[7]  P. Panayiotidis,et al.  Genetics of small lymphocyte disorders. , 1999, Seminars in hematology.

[8]  C. Kittas,et al.  B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. , 1999, Seminars in hematology.

[9]  F. Mackay,et al.  The Sequential Role of Lymphotoxin and B Cells in the Development of Splenic Follicles , 1998, The Journal of experimental medicine.

[10]  G. Juliusson,et al.  Cytogenetics in chronic lymphocytic leukemia. , 1998, Seminars in oncology.

[11]  U. Weidle,et al.  Complex expression pattern of the TNF region gene LST1 through differential regulation, initiation, and alternative splicing. , 1997, Genomics.

[12]  G. Salles,et al.  Identification of two lymphotoxin beta isoforms expressed in human lymphoid cell lines and non-Hodgkin's lymphomas. , 1997, Biochemical and biophysical research communications.

[13]  S. Nedospasov,et al.  Functional analysis of the lymphotoxin-beta promoter. Sequence requirements for PMA activation. , 1996, Journal of immunology.

[14]  F. Ajchenbaum‐Cymbalista,et al.  Overexpression of cyclin D2 in chronic B-cell malignancies. , 1995, Blood.

[15]  B. Dörken,et al.  Lymphotoxin‐α/β heterodimer is expressed on leukemic hairy cells and activated human B lymphocytes , 1994 .

[16]  R. Siebert,et al.  Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23). , 1994, Blood.

[17]  C. Ware,et al.  A lymphotoxin-beta-specific receptor. , 1994, Science.

[18]  C. Bloomfield,et al.  Cytogenetics of indolent lymphomas. , 1993, Seminars in Oncology.

[19]  Carl F. Ware,et al.  Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface , 1993, Cell.

[20]  J L Browning,et al.  Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. , 1992, Journal of immunology.

[21]  A. Sappino,et al.  Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients. , 1990, Blood.

[22]  F. Rodeghiero,et al.  Prognostic significance of CD56 antigen expression in acute myeloid leukemia. , 2002, Haematologica.

[23]  L. Bullinger,et al.  Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.

[24]  M Vihinen,et al.  Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion , 2001, Leukemia.

[25]  John Calvin Reed,et al.  bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. , 1993, Blood.

[26]  G. Inghirami,et al.  Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia. , 1988, Blood.